Mochida Pharmaceutical Co., Ltd. - Product Pipeline Review - 2012

Summary

“Mochida Pharmaceutical Co., Ltd. - Product Pipeline Review - 2012” provides data on the Mochida Pharmaceutical Co., Ltd.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Mochida Pharmaceutical Co., Ltd.’s corporate website, SEC filings, investor presentations and featured press releases, both from Mochida Pharmaceutical Co., Ltd. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Mochida Pharmaceutical Co., Ltd. - Brief Mochida Pharmaceutical Co., Ltd. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Mochida Pharmaceutical Co., Ltd. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Mochida Pharmaceutical Co., Ltd. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Mochida Pharmaceutical Co., Ltd.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Mochida Pharmaceutical Co., Ltd.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Mochida Pharmaceutical Co., Ltd. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Mochida Pharmaceutical Co., Ltd.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Mochida Pharmaceutical Co., Ltd..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Mochida Pharmaceutical Co., Ltd. and identify potential opportunities in those areas.

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Mochida Pharmaceutical Co., Ltd. Snapshot 5
Mochida Pharmaceutical Co., Ltd. Overview 5
Key Information 5
Key Facts 5
Mochida Pharmaceutical Co., Ltd. – Research and Development Overview 6
Key Therapeutic Areas 6
Mochida Pharmaceutical Co., Ltd. – Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products –  Monotherapy 10
Mochida Pharmaceutical Co., Ltd. – Pipeline Products Glance 11
Mochida Pharmaceutical Co., Ltd. – Late Stage Pipeline 11
Registration Filed Products/Combination Treatment Modalities 11
Phase III Products/Combination Treatment Modalities 12
Mochida Pharmaceutical Co., Ltd. Clinical Stage Pipeline Products 13
Phase II Products/Combination Treatment Modalities 13
Mochida Pharmaceutical Co., Ltd. – Drug Profiles 14
dienogest 14
Product Description 14
Mechanism of Action 14
R&D Progress 14
filgrastim 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
icosapent ethyl 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
mesalamine 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
Rituximab Biosimilar 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
Trastuzumab Biosimilar 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
treprostinil 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
Mochida Pharmaceutical Co., Ltd. – Pipeline Analysis 21
Mochida Pharmaceutical Co., Ltd. – Pipeline Products by Therapeutic Class 21
Mochida Pharmaceutical Co., Ltd. – Pipeline Products by Route of Administration 22
Mochida Pharmaceutical Co., Ltd. – Pipeline Products By Mechanism of Action 23
Mochida Pharmaceutical Co., Ltd. –  Recent Pipeline Updates 24
Mochida Pharmaceutical Co., Ltd. - Dormant Projects 25
Mochida Pharmaceutical Co., Ltd. - Discontinued Pipeline Products 26
Discontinued Pipeline Product Profiles 26
ulinastatin 26
Mochida Pharmaceutical Co., Ltd. – Company Statement 27
Mochida Pharmaceutical Co., Ltd. – Locations And Subsidiaries 29
Head Office 29
Other Locations & Subsidiaries 29
Financial Deals Landscape 30
Mochida Pharmaceutical Co., Ltd., Deals Summary 30
Mochida Pharmaceutical Co., Ltd., Pharmaceuticals & Healthcare, Deal Details 31
Partnerships 31
Fuji Pharma Enters Into Co-Development Agreement With Mochida Pharma 31
Mochida Pharma Enters Into Co-Marketing Agreement With Mitsubishi Tanabe Pharma 32
Taisho Pharma Enters Into Agreement With Mochida Pharma 33
Inverness Medical Japan Enters Into Co-Marketing Agreement With Mochida Pharma 34
JCR Pharma Enters Into Co-Development Agreement With Mochida Pharma 35
United Therapeutics Enters Into Co-Marketing Agreement With Mochida Pharma 36
Licensing Agreements 37
Mochida Pharma Enters Into Licensing Agreement With Merck 37
Gedeon Richter Enters Into Licensing Agreement With Mochida Pharma 38
Mochida Pharma Enters Into An Agreement With Shire Pharma 39
Mochida Pharma Signs An Agreement With Wyeth 43
Acquisition 44
Siemens K.K. Acquires Stake In Mochida Siemens Medical Systems From Mochida Pharma 44
Appendix 45
Methodology 45
Coverage 45
Secondary Research 45
Primary Research 45
Expert Panel Validation 45
Contact Us 46
Disclaimer 46

List of Tables
Mochida Pharmaceutical Co., Ltd., Key Information 5
Mochida Pharmaceutical Co., Ltd., Key Facts 5
Mochida Pharmaceutical Co., Ltd. – Pipeline by Indication, 2012 7
Mochida Pharmaceutical Co., Ltd. – Pipeline by Stage of Development, 2012 9
Mochida Pharmaceutical Co., Ltd. – Monotherapy Products in Pipeline, 2012 10
Mochida Pharmaceutical Co., Ltd. – Filed, 2012 11
Mochida Pharmaceutical Co., Ltd. – Phase III, 2012 12
Mochida Pharmaceutical Co., Ltd. – Phase II, 2012 13
Mochida Pharmaceutical Co., Ltd. – Pipeline By Therapeutic Class, 2012 21
Mochida Pharmaceutical Co., Ltd. – Pipeline By Route of Administration, 2012 22
Mochida Pharmaceutical Co., Ltd. – Pipeline Products By Mechanism of Action, 2012 23
Mochida Pharmaceutical Co., Ltd. – Recent Pipeline Updates, 2012 24
Mochida Pharmaceutical Co., Ltd. - Dormant Developmental Projects,2012 25
Mochida Pharmaceutical Co., Ltd. - Discontinued Pipeline Products, 2012 26
Mochida Pharmaceutical Co., Ltd., Subsidiaries 29
Mochida Pharmaceutical Co., Ltd., Deals Summary 30
Fuji Pharma Enters Into Co-Development Agreement With Mochida Pharma 31
Mochida Pharma Enters Into Co-Marketing Agreement With Mitsubishi Tanabe Pharma 32
Taisho Pharma Enters Into Agreement With Mochida Pharma 33
Inverness Medical Japan Enters Into Co-Marketing Agreement With Mochida Pharma 34
JCR Pharma Enters Into Co-Development Agreement With Mochida Pharma 35
United Therapeutics Enters Into Co-Marketing Agreement With Mochida Pharma 36
Mochida Pharma Enters Into Licensing Agreement With Merck 37
Gedeon Richter Enters Into Licensing Agreement With Mochida Pharma 38
Mochida Pharma Enters Into An Agreement With Shire Pharma 39
Mochida Pharma Signs An Agreement With Wyeth 43
Siemens K.K. Acquires Stake In Mochida Siemens Medical Systems From Mochida Pharma 44

List of Figures
Mochida Pharmaceutical Co., Ltd.  – Pipeline by Indication, 2012 7
Mochida Pharmaceutical Co., Ltd.  – Pipeline by Stage of Development, 2012 9
Mochida Pharmaceutical Co., Ltd. – Monotherapy Products in Pipeline, 2012 10
Mochida Pharmaceutical Co., Ltd.  – Pipeline By Therapeutic Class, 2012 21
Mochida Pharmaceutical Co., Ltd.  – Pipeline By Route of Administration, 2012 22
Mochida Pharmaceutical Co., Ltd.  - Pipeline Products By Mechanism of Action, 2012 23